Archives
ESG 2009 Roma
Satellite Symposium at the 8th Congress of the European Society of Gynecology
Selective progesterone receptor modulators (SPRM) are a new class of compounds with great potential in the treatment of uterine fibroids. The presentations in this symposium discussed the pharmacology of SPRM and their effect on the endometrium, before moving on to review recent clinical outcomes with SPRM and identifying how they might be used in the management of uterine fibroids.
EBCOG 2010 Antwerp
SPRMs: Towards a New Medical Treatment for Uterine Fibroids
Selective Progesterone Receptor Modulators (SPRM) are a new class of compounds that offer a promising new treatment option for uterine fibroids. The presentations in this symposium discussed the pharmacology and mode of action of SPRM, the clinical development of SPRM and the recent clinical data of ulipristal acetate from the PEARL studies.
Our faculty of leading experts hosted a discussion on the role of SPRMs in the medical treatment of uterine fibroids according to ulipristal acetate clinical data and highlighted points relevant to clinical practice.
ESG 2011 Copenhagen
New Medical Management of Uterine Fibroids: The Mounting Evidence with Ulipristal Acetate Clinical Data.
FIGO 2012 Roma
SATELLITE SYMPOSIUM AT THE 20TH FIGO WORLD CONGRESS 2012 IN ROME
ESG 2013 Brussels
OPENING SYMPOSIUM – LONG-TERM MEDICAL MANAGEMENT OF FIBROIDS WITH SPRMs
Selective Progesterone Receptor Modulators (SPRM) are a new class of compounds that are able to inhibits or stimulate molecular factors called Progesterone Response Elements, by recruiting transcriptional co-activators or co-repressors depending on the target tissue. The double action allows an accurate management of uterine fibroids and there are promising data even in endometriosis.
The presentations in this symposium discussed the clinical data of Ulipristal Acetate for repeated courses in the long term medical treatment, and highlighted relevant points coming from PEARL III & Extension clinical trials.
EBCOG 2014 Glasgow
Esmya®: the PEARL studies and clinical experience two years on 23rd European Congress of Obstetrics and Gynaecology. May 8th, 2014